The Genomic Characterization Of Primary And Metastatic Her2-Low Breast Cancers

The genomic characterization of primary and metastatic HER2-low breast cancers

The comprehensive genomic characterization of HER2-low breast cancer

The evolution of HER2-low breast cancer from primary to recurrence

A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer

PeerView Oncology

Clinical outcomes in women with metastatic HER2-low breast cancer in the real world

Genomic Analysis of CALGB 40601 for HER2-Positive Breast Cancer

Targeted Oncology

Genomic and transcriptomic landscape of HER2-low breast cancer

Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer

The Science of HER2-low Breast Cancer and Implications for the Pathology Team

ASCP

GS3-03: "Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations..."

San Antonio Breast Cancer Symposium

Genetic vs immune strategies in breast cancer

Genomic Characterization of CNS Metastases: Implications for Precision Medicine

Society for Translational Oncology

Genomic analysis of ovarian cancer metastasis: towards improved understanding treatment

School of Biological Sciences

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis

Advances in HER2-positive and HER2-low Breast Cancer

ASCP

Remaining questions on the management of HER2-low breast cancer

Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in Review

Total Health | Oncology

The evolution of HER2-low-positive breast cancer as a clinical subtype

Genomic Analysis of Inherited Breast and Ovarian Cancer

Remaining questions surrounding HER2-low breast cancer – how low can you go?